Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002426 · ClinicalTrials.gov registry record · NA

A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients

A NA study of HIV Infections, sponsored by Gilead Sciences.

Completed
Registry status
NA
Development phase
390
Enrollment target
20
Study locations

NCT00002426 is a NA study of HIV Infections that has completed, run by Gilead Sciences. The registered enrollment target is 390 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002426, a NA study of HIV Infections, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
NA
Development phase
390 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to see if it is safe and effective to give an experimental anti-HIV drug, adefovir dipivoxil (ADV), in combination with other anti-HIV drugs (HAART) to patients who have a viral load (level of HIV in the blood) between 50 and 400 copies/ml.

Conditions Studied

HIV Infections

Interventions

  • DRUG Adefovir dipivoxil

Study Locations (20)

California

  • Pacific Oaks Research - Beverly Hills
  • ViRx Inc - Palm Springs
  • Ctr for AIDS Research / Education and Service (CARES) - Sacramento
  • San Francisco Gen Hosp / UCSF AIDS Program - San Francisco
  • Kaiser Foundation Hospital - San Francisco
  • San Francisco VA Med Ctr - San Francisco

Florida

  • IDC Research Initiative - Altamonte Springs
  • Community AIDS Resource Inc - Coral Gables
  • TheraFirst Med Ctrs Inc - Fort Lauderdale
  • Duval County Health Department - Jacksonville
  • Health Positive - Safety Harbor
  • Center for Quality Care - Tampa

District of Columbia

  • Georgetown Univ Med Ctr - Washington D.C.
  • Dupont Circle Physicians Group - Washington D.C.
  • George Washington Univ Med Ctr - Washington D.C.

Connecticut

  • Blick Med Associates - Stamford

Georgia

  • Georgia Research Associates - Atlanta

Illinois

  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Indiana

  • Indiana Univ Infectious Disease Research Clinic - Indianapolis

Maryland

  • Johns Hopkins Univ School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 390 participants
Phase NA

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002426

The ClinicalTrials.gov registry entry for NCT00002426 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (12% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Adefovir dipivoxil is the first listed.

NCT00002426 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00002426 about?

NCT00002426 is a clinical study titled "A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients". The purpose of this study is to see if it is safe and effective to give an experimental anti-HIV drug, adefovir dipivoxil (ADV), in combination with other anti-HIV drugs (HAART) to patients who have a viral load (level of HIV in the blood) between 50 and 400 copies/ml.

What is the current status of trial NCT00002426?

This trial is currently completed. It is a NA study. The enrollment target is 390 participants.

What conditions does trial NCT00002426 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002426?

The interventions under investigation include: Adefovir dipivoxil (DRUG).

Who is sponsoring clinical trial NCT00002426?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002426 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.